TY - JOUR
T1 - Attenuating the defeminization of the neonatal rat brain
T2 - Mechanisms of action of cyproterone acetate, 1,4,6-androstatriene-3,17,-dione and a synthetic progestin, R5020
AU - McEwen, Bruce S.
AU - Lieberburg, Ivan
AU - Chaptal, Claude
AU - Davis, Paula G.
AU - Krey, Lewis C.
AU - MacLusky, Neil J.
AU - Roy, Edward J.
N1 - Funding Information:
ResearchissuppobryteNdIH GrantsNS07080(toB.M~.) andHD10168(toL.C.K.)andby an institutionalg rantR F70095f rom the Rockefeller Foundationf or researchi n reproductive biology. Neil MacLusky was supported by postdoctoral fellowships from the Science Research Council, Great Britain, and by the Camille and Henry Dreyfus Foundation, Inc., New York. NIH Fellowship supporti s as follows: MH-05781( P.G.D.); MH-05972( E.J.R.). We wish to thank Mrs. Oksana Wengerchukf or editorial assistancea nd Ms. Winifred Berg Elton for graphics work. We also thank Mr. Evan Elkin and Ms. Valerie DeGroff for assistancei n preparing newborn rats used in Experiment 2.
PY - 1979/12
Y1 - 1979/12
N2 - Although defeminization of the rat brain appears to depend significantly on the conversion of testosterone (T) to estradiol (E2), the antiandrogenic steroid cyproterone acetate (CA) is able to attenuate defeminization. In order to study the mechanism of action of CA on brain sexual differentiation, newborn male rats were given subcutaneous injections of this steroid on postnatal Days 2-6. When castrated on Day 70 and given estrogen and progesterone, these CA-treated males displayed elevated lordosis quotients (LQ) compared to controls. CA-treated neonatal males were also examined at the end of the drug treatment to ascertain the mechanism of drug action: (1) Serum T levels were normal; (2) Brain cell nuclear estrogen receptor occupation, estimated by an exchange assay, was reduced by ≈ 30% in the brains of the CA-treated males, although the ability of exogenous E2 to occupy these brain estrogen receptors was not reduced. Other work has demonstrated a weak competitive effect of cyproterone on aromatization, and thus cyproterone acetate may have interfered with the conversion of T to E2 CA also has progestogenic activity, and 5-mm capsules of a potent synthetic progestin, R5020, given to newborn male rats on Days 2-6, are shown to elevate the LQ after postnatal Day 70 to the same extent as CA. However, R5020 did not reduce estrogen receptor occupation in the neonatal male rat brain and was without effect on serum T levels in the neonatal male. Because of the implied role of T-derived estrogens in defeminization, an experiment was conducted showing that the defeminizing action of estradiol benzoate given to 3-day-old female rat pups is attenuated by the antiestrogen, CI628, and not by the potent inhibitor of aromatization, 1,4,6-androstatriene-3,17-dione (ATD). This result complements previous experiments showing that both ATD and CI628 attenuate the defeminization produced by T. Taken together, the results lend further support to a pivotal role for aromatization and for estrogen-receptor interactions in the defeminizing effects of T. The actions of progestins such as CA and R5020 in attenuating defeminization are discussed in relation to the recent demonstration of progestin receptors in the neonatal rat brain. It is concluded that CA may act by a combination of actions, both by inhibiting aromatization and by acting as a progestin.
AB - Although defeminization of the rat brain appears to depend significantly on the conversion of testosterone (T) to estradiol (E2), the antiandrogenic steroid cyproterone acetate (CA) is able to attenuate defeminization. In order to study the mechanism of action of CA on brain sexual differentiation, newborn male rats were given subcutaneous injections of this steroid on postnatal Days 2-6. When castrated on Day 70 and given estrogen and progesterone, these CA-treated males displayed elevated lordosis quotients (LQ) compared to controls. CA-treated neonatal males were also examined at the end of the drug treatment to ascertain the mechanism of drug action: (1) Serum T levels were normal; (2) Brain cell nuclear estrogen receptor occupation, estimated by an exchange assay, was reduced by ≈ 30% in the brains of the CA-treated males, although the ability of exogenous E2 to occupy these brain estrogen receptors was not reduced. Other work has demonstrated a weak competitive effect of cyproterone on aromatization, and thus cyproterone acetate may have interfered with the conversion of T to E2 CA also has progestogenic activity, and 5-mm capsules of a potent synthetic progestin, R5020, given to newborn male rats on Days 2-6, are shown to elevate the LQ after postnatal Day 70 to the same extent as CA. However, R5020 did not reduce estrogen receptor occupation in the neonatal male rat brain and was without effect on serum T levels in the neonatal male. Because of the implied role of T-derived estrogens in defeminization, an experiment was conducted showing that the defeminizing action of estradiol benzoate given to 3-day-old female rat pups is attenuated by the antiestrogen, CI628, and not by the potent inhibitor of aromatization, 1,4,6-androstatriene-3,17-dione (ATD). This result complements previous experiments showing that both ATD and CI628 attenuate the defeminization produced by T. Taken together, the results lend further support to a pivotal role for aromatization and for estrogen-receptor interactions in the defeminizing effects of T. The actions of progestins such as CA and R5020 in attenuating defeminization are discussed in relation to the recent demonstration of progestin receptors in the neonatal rat brain. It is concluded that CA may act by a combination of actions, both by inhibiting aromatization and by acting as a progestin.
UR - http://www.scopus.com/inward/record.url?scp=0018628761&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018628761&partnerID=8YFLogxK
U2 - 10.1016/0018-506X(79)90044-8
DO - 10.1016/0018-506X(79)90044-8
M3 - Article
C2 - 575953
AN - SCOPUS:0018628761
SN - 0018-506X
VL - 13
SP - 269
EP - 281
JO - Hormones and Behavior
JF - Hormones and Behavior
IS - 3
ER -